SecBot SecBot
8-K ·Filed Jul 30, 2026

BMY

BRISTOL MYERS SQUIBB CO
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0000014272-26-000018
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong beat and raised guidance confirm accelerating Growth Portfolio momentum and successful pipeline execution. Watch for upcoming PDUFA catalysts: iberdomide (August 17, 2026) and mezigdomide (May 13, 2027) in multiple myeloma, which could further derisk the long-term growth story. The raised Eliquis guidance (20-25% growth) is a positive surprise given prior generic concerns.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

BMY drug pipeline →

iberdomide

● Neutral Named in this 8-K
Impact
Phase
Filed / PDUFA pending (NDA under FDA review; pivotal program completed)
Time to market
FDA decision due August 17, 2026 (~2 weeks away); if approved, commercial launch would follow later in 2026.
Next catalyst
None dated

What to watchMark August 17, 2026 on the calendar: the FDA target action date for iberdomide in relapsed/refractory multiple myeloma. An approval would give BMY a potential first-in-class oral CELMoD (next-gen successor to its Revlimid/Pomalyst franchise) and is likely a modestly positive headline; a CRL or review extension is the bigger downside risk to watch. Because iberdomide is a small slice of a mega-cap with a rich pipeline (mezigdomide PDUFA already cited for May 2027), treat the decision as a franchise-confidence signal, not a standalone trade.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$64.86
T+0 close · Jul 30, 2026 · via day close
Latest settled
−5.21%
T+60 · $61.48
Vs SPY
−7.68%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 30 $64.86entry
  2. T+1 · 4mo ago +0.69%α −0.01% · $65.31
  3. T+5 · 3mo ago −1.09%α −4.72% · $64.15
  4. T+20 · 3mo ago +3.22%α −0.74% · $66.95
  5. T+60 · 25d ago −5.21%α −7.68% · $61.48
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Bristol Myers Squibb reported Q2 2026 results significantly above consensus, with non-GAAP EPS of $2.04 beating the $1.60 estimate by 27.7% and revenue of $13.0B exceeding the $11.74B consensus. The company raised its full-year 2026 revenue guidance to $49.0B-$50.0B (from $46.0B-$47.5B) and non-GAAP EPS guidance to $6.75-$7.00 (from $6.05-$6.35), driven by 15% Growth Portfolio revenue growth and broad-based momentum.

Key Financial Metrics

EPS
$2.04
est $1.60 · +27.5%
Revenue
$13.0B
est $11.7B · +10.5% · +6.0% YoY
Rating
strong beat
Guidance
$49.0B-$50.0B
raised
Gross Margin
71.3%

Key Facts

  • Q2 2026 total revenues of $12.973B, up 6% YoY (+5% Ex-FX), vs consensus $11.74B
  • Non-GAAP EPS of $2.04, up 40% YoY from $1.46, beating consensus of $1.60 by 27.7%
  • GAAP EPS of $1.62, up 153% YoY from $0.64
  • Growth Portfolio revenues of $7.6B, up 15% YoY (+14% Ex-FX), driven by Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, and Opdualag
  • Legacy Portfolio revenues of $5.4B, down 4% YoY (-5% Ex-FX), with Eliquis up 22% offset by generic erosion on Revlimid (-49%), Pomalyst/Imnovid (-71%), and Sprycel (-27%)
  • Full-year 2026 revenue guidance raised to $49.0B-$50.0B (from $46.0B-$47.5B)
  • Full-year 2026 non-GAAP EPS guidance raised to $6.75-$7.00 (from $6.05-$6.35)
  • Eliquis 2026 WW revenue growth guidance raised to 20%-25% (from 10%-15%)
  • Operating expenses guidance increased to ~$16.5B (from $16.3B) for pipeline and launch investments
  • Net debt position improved to $31.656B from $34.043B at year-end 2025
  • Cash flow from operations was $3.4B in Q2 2026
  • ~$5B share repurchase authorization remaining as of June 30, 2026

Financial Impact

Revenue beat consensus by $1.23B (10.5%); non-GAAP EPS beat by $0.44 (27.7%); full-year guidance raised by $3.0B-$2.5B on revenue and $0.70-$0.65 on EPS

revenueepsguidancegrowth portfolioeliquis

Risk Factors

  • Legacy Portfolio continues to decline (-4% in Q2) as generic erosion on Revlimid (-49%) and Pomalyst/Imnovid (-71%) accelerates
  • Gross margin contracted 120bps YoY to 71.3% (GAAP) due to product mix shift toward Growth Portfolio
  • Operating expenses rising to $16.5B guidance reflects increased R&D and launch spending, pressuring near-term margins
  • Net debt of $31.7B remains elevated, limiting financial flexibility for large M&A

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
40% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000014272-26-000018
Document: bmy-20260730.htm0000014272-26-000018
Document: q22026earningspresentati.htm0000014272-26-000018
Document: 0000014272-26-000018-index-headers.html0000014272-26-000018
Document: 0000014272-26-000018-index.html0000014272-26-000018
Document: 0000014272-26-000018.txt0000014272-26-000018
8-K Data (Synthetic)0000014272-26-000018

Track record

9 reports on BMY

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 6, 202610d ago 144 Neutral 2/10 Entry $62.14 to $62.14 Now $62.93 +1.27% · 0.00% −2.37% vs SPY
  2. Oct 29, 202618d ago 8-K Neutral 5/10 Entry $61.39 to $62.48 Now $62.93 +2.51% ▲ +1.78% +3.55% vs SPY
  3. Oct 23, 202624d ago Institutional Cluster Neutral 3/10 Entry $61.48 to $61.61 Now $62.93 +2.36% ▲ +0.21% −0.50% vs SPY
  4. Oct 5, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
  5. Aug 17, 202613w ago Institutional Cluster Bullish 6/10 Entry $64.63 to $66.05 Now $62.93 −2.63% ▲ +2.20% +2.87% vs SPY
  6. Aug 5, 202614w ago ANALYST-UPGRADE Bullish 4/10 Entry $63.63 to $64.15 Now $62.93 −1.10% ▲ +0.82% +0.98% vs SPY
  7. Jul 30, 202615w ago 8-K Bullish 7/10 Viewing Entry $64.86 to $65.31 Now $62.93 −2.98% ▲ +0.69% −0.01% vs SPY
  8. Mar 25, 202633w ago DEFA14A Neutral 3/10 Entry $59.39 to $58.47 Now $62.93 +5.97% ▼ −1.55% +0.13% vs SPY
  9. Feb 26, 202637w ago Court Ruling Neutral 3/10 Entry $62.37 to $62.34 Now $62.93 +0.90% ▼ −0.05% −0.10% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens in 8h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026